Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Clinical trial NCT07518706 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07518706
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-30
- Primary completion
- 2028-12-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.